Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 mars 2026 08h00 HE | Source: Tangram Therapeutics PLC

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 ...
26 nov. 2025 04h00 HE | Source: Tangram Therapeutics PLC

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...
01 oct. 2025 07h00 HE | Source: Tangram Therapeutics PLC

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025. Introducing LLibra OS, a next-generation AI platform that accelerates discovery and...
31 oct. 2024 09h00 HE | Source: e-therapeutics plc

e-therapeutics Announces Business Updates and Interim Results

LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...